How to Find Strong Buy Medical Stocks Using the Zacks Rank
It doesn't matter if you're a growth, value, income, or momentum-focused investor -- building a successful investment portfolio takes skill, research, and a little bit of luck.
Should You Buy #1 (Strong Buy)-Ranked Lantheus Holdings (LNTH) for Your Portfolio?
Lantheus Holdings was upgraded to the Zacks Rank #1 list on March 14, 2024. The Zacks Rank is a unique stock-rating model that helps you take advantage of earnings estimate revision trends and provides a way to get into stocks highly sought after by institutional investors.
Lantheus Holdings, Inc. is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes. It classifies its products into three categories — Precision Diagnostics (30.1% of FY23 revenues, up 9.4% from FY22), Radiopharmaceutical Oncology (65.9%, up 60.8%), and Strategic Partnerships and Other Revenue (4%, up 10.7%).
Five analysts revised their earnings estimate upwards in the last 60 days for fiscal 2024. The Zacks Consensus Estimate has increased $0.33 to $6.58 per share. LNTH boasts an average earnings surprise of 14.8%.
Analysts are expecting earnings to grow 5.6% for the current fiscal year, with revenue forecasted to rise 10.3%.
Additionally, LNTH has climbed higher over the past four weeks, gaining 3.6%. The S&P 500 is up 3.3% in comparison.
Bottom Line
With a #1 (Strong Buy) ranking, positive trend in earnings estimate revisions, and strong market momentum, Lantheus Holdings could be just the stock to help your portfolio generate returns that could fund your retirement, your kids' college tuition, or your short- and long-term savings goals.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
